Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07582133
PHASE2
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
Sponsor: Chengdu Suncadia Medicine Co., Ltd.
View on ClinicalTrials.gov
Summary
This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these patients.
Official title: A Multicenter, Open-label Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 Capsules in Patients With Primary IgA Nephropathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
380
Start Date
2026-07-06
Completion Date
2029-11
Last Updated
2026-07-22
Healthy Volunteers
No
Conditions
Interventions
DRUG
HRS-5965 Capsules
HRS-5965 Capsules
Locations (1)
Peking University First Hospital
Beijing, Beijing Municipality, China